[1-Cyclopropyl-2-(3-fluorophenoxy)-ethyl]methylamine
![]() |
- $320 - $904
- Product name: [1-Cyclopropyl-2-(3-fluorophenoxy)-ethyl]methylamine
- CAS: 1341502-50-8
- MF: C12H16FNO
- MW: 209.2599432
- EINECS:
- MDL Number:MFCD19605942
- Synonyms:[1-Cyclopropyl-2-(3-fluorophenoxy)-ethyl]methylamine;Cyclopropanemethanamine, α-[(3-fluorophenoxy)methyl]-N-methyl-
4 prices
Selected condition:
Brand
- Crysdot
- Matrix Scientific
Package
- 500mg
- 1g
- 5g
- ManufacturerCrysdot
- Product numberCD12152785
- Product description1-Cyclopropyl-2-(3-fluorophenoxy)-N-methylethanamine 97%
- Packaging1g
- Price$320
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD12152785
- Product description1-Cyclopropyl-2-(3-fluorophenoxy)-N-methylethanamine 97%
- Packaging5g
- Price$904
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number080411
- Product description[1-Cyclopropyl-2-(3-fluorophenoxy)-ethyl]methylamine
- Packaging500mg
- Price$336
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number080411
- Product description[1-Cyclopropyl-2-(3-fluorophenoxy)-ethyl]methylamine
- Packaging1g
- Price$420
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Crysdot | CD12152785 | 1-Cyclopropyl-2-(3-fluorophenoxy)-N-methylethanamine 97% | 1g | $320 | 2021-12-16 | Buy |
Crysdot | CD12152785 | 1-Cyclopropyl-2-(3-fluorophenoxy)-N-methylethanamine 97% | 5g | $904 | 2021-12-16 | Buy |
Matrix Scientific | 080411 | [1-Cyclopropyl-2-(3-fluorophenoxy)-ethyl]methylamine | 500mg | $336 | 2021-12-16 | Buy |
Matrix Scientific | 080411 | [1-Cyclopropyl-2-(3-fluorophenoxy)-ethyl]methylamine | 1g | $420 | 2021-12-16 | Buy |
Properties
Boiling point :286.9±20.0 °C(Predicted)
Density :1.120±0.06 g/cm3(Predicted)
pka :9.51±0.20(Predicted)
Density :1.120±0.06 g/cm3(Predicted)
pka :9.51±0.20(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|